The purpose of this study is to determine if adding ramucirumab in combination with capmatinib and osimertinib is effective in treating patients with Stage 4 or recurrent non-small cell lung cancer.
Contact phone
Tracy Bellefeuil | (517) 364-2835
Contact email
[email protected]
Principal investigator
Dr. Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Metastatic Non-Small Cell Lung
Webform